Is elevation of N-terminal pro-B-type natriuretic peptide at discharge associated with 2-year composite endpoint of all-cause mortality and heart failure hospitalisation after transcatheter aortic valve implantation? Insights from a multicentre prospective OCEAN-TAVI registry in Japan

Kazuki Mizutani, Masahiko Hara, Mana Nakao, Tsukasa Okai, Keiko Kajio, Takashi Murakami, Toshihiko Shibata, Minoru Yoshiyama, Toru Naganuma, Futoshi Yamanaka, Akihiro Higashimori, Norio Tada, Kensuke Takagi, Motoharu Araki, Hiroshi Ueno, Minoru Tabata, Shinichi Shirai, Yusuke Watanabe, Masanori Yamamoto, Kentaro Hayashida

ABSTRACT

Objectives The aim of this study was to investigate the 2-year prognostic impact of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at discharge following transcatheter aortic valve implantation (TAVI).

Design Multicentre prospective observational study.

Settings Seven institutions from multicentre, observational registry of symptomatic patients with severe aortic stenosis who undergo TAVI.

Participants We enrolled 500 consecutive patients who underwent TAVI with measurements of NT-proBNP at discharge between 2013 and 2016. Study patients were stratified into two groups according to survival classification and regression tree (CART) analysis: high versus low NT-proBNP groups.

Interventions The impact of high NT-proBNP on a 2-year composite endpoint consisting of all-cause mortality and heart failure hospitalisation was evaluated using a multivariable Cox model.

Results Median age was 86 years (quartile 82–89), and 24.2% of the study population were men. Median Society of Thoracic Surgeon score was 7.1 (5.1–9.8), and NT-proBNP at discharge was 1381 (653–3136) pg/mL. The composite endpoint incidence was 13.0% (95% CI 9.6% to 16.3%) at 1 year and 22.3% (95% CI 16.1%–27.9%) at 2 years. The survival CART analysis revealed that the NT-proBNP level required to discern the 2-year composite endpoint was 4288 pg/mL. Elevated NT-proBNP had a statistically significant impact on outcomes, with adjusted HR of 2.21 (95% CI 1.21 to 4.04, \( p=0.010 \)), and with a significant sex difference (\( P \) for interaction=0.003).

Strengths and limitations of this study

The study has a multicentre prospective design. The size of the study population is the largest ever (n=500). A survival classification and regression tree analysis was used for a simple risk stratification with a single biomarker. The N-terminal pro-B-type natriuretic peptide was not measured at a core laboratory. Heart failure hospitalisation was determined by each individual physician’s judgement.

Conclusion Elevation of NT-proBNP at discharge is associated with higher incidence of the 2-year composite endpoint after TAVI.

Trial registration number 000020423

INTRODUCTION

Severe aortic stenosis (AS) is one of the most prevalent forms of heart valve disease. AS causes left ventricular pressure overload, which leads to acute decompensated heart failure (HF) and high cardiovascular mortality. Surgical aortic valve replacement (SAVR) has been the mainstay of treatment for symptomatic severe AS for decades. Transcatheter aortic valve implantation (TAVI) has also recently been recognised as a promising therapeutic option and has been reported to
have non-inferior long-term clinical outcome in patients with intermediate surgical risk who underwent TAVI as compared with a SAVR cohort.\textsuperscript{3,5} With the expanding indication and prolongation of life expectancy after TAVI, it is speculated that risk stratification and long-term management of HF may be the next challenge facing physicians.\textsuperscript{3-6} For example, a recent meta-analysis that predominantly included intermediate-risk patients with AS demonstrated that transfemoral TAVI is associated with more severe HF symptoms than SAVR during 2-year follow-up.\textsuperscript{6}

N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a hormone released by the cardiac ventricles as a result of elevated end-diastolic pressure overload.\textsuperscript{7} NT-proBNP has been used for stratification of long-term mortality in patients with chronic HF.\textsuperscript{1,2,7-9} Although several reports have evaluated the relationship between NT-proBNP levels and the postprocedural prognosis of the TAVI cohort, these reports had some limitations. For example, all reports were derived from a single centre with relatively small numbers of patients, and most studies evaluated NT-proBNP prior to performance of the TAVI procedure.\textsuperscript{10-15} Since TAVI could dramatically release the left ventricle from pressure overload and contribute to the decrease in NT-proBNP level, we speculated that it is preferable to use NT-proBNP levels at discharge for risk stratification of long-term prognosis in patients who underwent TAVI.\textsuperscript{15,16} Finally, the risk of hospitalisation for HF following TAVI was not investigated in most NT-proBNP studies.\textsuperscript{10-15} Consequently, a multicentre TAVI study of the long-term prognostic impact of NT-proBNP levels at discharge warrants consideration. In the present study, we investigated NT-proBNP levels at discharge in terms of their impact on the 2-year composite endpoint of all-cause mortality and hospitalisation for HF, and usefulness for risk stratification in patients with AS who underwent TAVI. This was the largest study population ever enrolled (n=500) from a multicentre, prospective TAVI registry.

**METHODS**

**Study population**

Figure 1 shows patient selection flow. Study candidates included 500 consecutive patients from 7 of 14 institutions where NT-proBNP was measured at discharge, who were enrolled in the Optimised Transcatheter Valvular Intervention (OCEAN)-TAVI registry. The enrolled patients were discharged alive from the hospital and had a record of NT-proBNP at discharge, without active cancer present, between October 2013 and July 2016 (Figure 1).\textsuperscript{17} The OCEAN-TAVI is a prospective, multicentre, observational registry of symptomatic patients with severe AS who undergo TAVI using the Edwards Sapien XT/Sapien 3 Transcatheter Heart Valve (Edwards Lifesciences, Irvine, California, USA) or the Medtronic CoreValve Revalving System (Medtronic, Minneapolis, Minnesota, USA) at 14 collaborating hospitals. This trial was registered with the University Hospital Medical Information Network Clinical Trials Registry, as accepted by the International Committee of Medical Journal Editors (UMIN-ID:000020423). Inclusion criteria were: (1) the presence of HF symptoms defined as New York Heart Association (NYHA) functional class II; (2) the presence of degenerative AS; (3) a mean gradient of >40 mm Hg or a jet velocity of >4.0 m/s; and/or (4) an aortic valve area (AVA) <1.0 cm\(^2\) (or an effective orifice area (EOA) index <0.6 cm\(^2\)/m\(^2\)). Indication for TAVI was determined based on the clinical consensus of a heart team comprised of cardiac surgeons, interventional cardiologists, anaesthesiologists and imaging specialists. Exclusion criteria were: (1) presence of a non-calcified aortic valve; (2) failed surgical bioprosthesis implantation; (3) presence of severe aortic regurgitation (AR); and/or (4) the current use of dialysis. The study protocol was developed in accordance with the Declaration of Helsinki. All patients gave written informed consent prior to participating in this study. All authors had full access to the data and were responsible for its integrity, and have read and authorised the publication of the manuscript in its current form.

**Blood sampling and NT-proBNP measurement**

Among 14 participating institutions in the OCEAN-TAVI registry, NT-proBNP at discharge was measured at seven institutions with a daily clinical practice. Blood samples were drawn from the antecubital or other accessible veins such as the dorsal hand vein, and collected in blood sampling tubes at the time of hospital discharge following TAVI procedure. NT-proBNP levels were measured using a chemiluminescence microparticle immunoassay (Elecys NT-proBNP, Roche Diagnostics, Tokyo, Japan) at five of the seven institutions (n=374), or a chemiluminescence enzyme immunoassay (HISCL NT-proBNP, Sysmex Corporation, Kobe, Japan) at two institutions (n=126). All samples were measured at each institutional laboratory and was not measured at a core laboratory. However, these two assays are reported to be highly comparable, with r=0.998; the least square formula is y=0.94x–38.69 in the product literature.
Data collection and statistical analysis

All data shown in tables and figures were collected from the OCEAN-TAVI multicentre prospective registry database. We set the primary endpoint as the 2-year composite of all-cause mortality and hospitalisation for HF after hospital discharge. The secondary endpoints were set as 2-year all-cause mortality and 2-year hospitalisation for HF, where the necessity of hospitalisation was determined based on the attending physician’s discretion. Although there were no definite prespecified criteria for HF rehospitalisation in the OCEAN-TAVI registry, the consensus indication includes patients with HF symptoms, such as dyspnoea with objective signs of volume overload, such as pulmonary oedema or signs of hypoperfusion, where the administration of intravenous diuresis or inotropic therapy should be considered.

The series of statistical analyses performed in this study was common in our previous report. Continuous variables were summarised using medians and IQR (quartiles 1 to 3), and categorical variables were summarised by means of counts and percentages. To provide a simple risk stratification model, we first classified our study means of counts and percentages. To provide a simple survival CART analysis for the primary patients into two groups according to survival classification and regression tree (CART) analysis for the primary endpoint.

We performed survival CART analysis using the primary endpoint as an outcome measure, with NT-proBNP levels at discharge as an independent variable. The purpose was to identify the cut-off value of NT-proBNP for the risk stratification of the primary endpoint. After the survival CART revealed the cut-off NT-proBNP value at discharge, we divided the study population into two groups based on this result. Patients with NT-proBNP levels lower than or equal to the cut-off value were defined as the ‘low NT-proBNP group,’ whereas those with NT-proBNP levels greater than the cut-off value were defined as the ‘high NT-proBNP group.’ We evaluated the impact of high NT-proBNP on endpoints as compared with that of low NT-proBNP, using univariable and multivariable Cox regression models, with a cross-product term between NT-proBNP groups and sex for the assessment of sex differences, and a P for interaction. The following variables were included as possible confounders: Clinical Frailty Scale; Society of Thoracic Surgeons (STS) surgical mortality risk score; apical approach; postprocedural transthoracic echocardiographic indices such as left ventricular ejection fraction (LVEF); EOA; mean aortic valve pressure gradient (mAVPG); the presence of moderate to severe AR; the presence of postprocedural acute kidney injury; and institution as a stratum to minimise institutional selection bias and maintain the validity. These confounders were determined clinically, considering the number of endpoints and multicollinearity. For example, information such as age, sex and arrhythmia data were included in the analysis since they are used in the calculation of the STS score. We also employed Akaike Information Criteria in order to select the best predictive Cox model for use. The incidence of each endpoint was estimated using the Kaplan-Meier method, with a 95% CI, and the difference between the NT-proBNP groups was evaluated using the log-rank test. Differences in continuous and categorical variables between NT-proBNP groups were compared using the Wilcoxon rank-sum test or the \( \chi^2 \) test, respectively. Although NT-proBNP levels on admission were available, we did not perform any analysis regarding the best timing of the measurements and did not evaluate whether a difference in the value between preprocedural and postprocedural NT-proBNP was more informative or not, considering the objective of the present study. There were no missing data regarding NT-proBNP at discharge and any additional statistical methods like imputation were not performed to address this. Statistical analyses were performed using R software packages (V.3.3.2; R Development Core Team). The significance level of statistical hypothesis testing was set at 0.05 and the alternative hypothesis was two-sided.

Patient and public involvement

Patients and the public were not involved in a development of the research question, outcome measures or recruitment to and conduct of the study. The study results will be disseminated to participants by publishing the study manuscript as written on the informed consent form.

RESULTS

The patients’ characteristics are shown in table 1. The median age of the study population was 86 years, and 24.2% of the patients were men. Almost all of the participants presented with NYHA HF functional class II or higher. The median Canadian Study of Health and Ageing Clinical Frailty Scale value was 4. Preoperative transthoracic echocardiography revealed that the median LVEF was 63% and the median AVA with Doppler method was 0.60 cm², with mAVPG of 47.9 mm Hg. The STS was 7.1% and the logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) was 13.5% (table 1). The median NT-proBNP level at discharge in the entire cohort was 1381 pg/mL (quartile: 653–3136), without statistical difference between men and women (p=0.065) or between patients with or without moderate to severe AR after TAVI (p=0.560); the distribution is presented in figure 2. NT-proBNP levels at discharge were 2382 (1143–3422) pg/mL in patients who underwent a transapical approach versus 1208 (544–2818) pg/mL in patients who underwent a transfemoral approach (p<0.001). The median interval from the time of TAVI to NT-proBNP measurement was 9 (7–15) days, and hospitalisation length was 10 (7–16) days.

Table 2 shows the information related to the TAVI procedure. Most of the patients in this study received the SAPIEN XT valve (Edwards Lifesciences, Irvine, CA, USA) with a median valve size of 23 mm. The percentage of patients who underwent the TAVI procedure with a transapical approach was 21.6%. Echocardiography revealed that postprocedural mAVPG was 10.5 mm Hg and EOA...
### Table 1 Patient characteristics

| Parameters                              | Total n=500 | Low NT-proBNP n=421 | High NT-proBNP n=79 | P value |
|-----------------------------------------|-------------|----------------------|---------------------|---------|
| **NT-proBNP at discharge (pg/mL)**      |             |                      |                     |         |
| Total population                        | 1381 (653–3136) | 1152 (544–2211) | 6396 (5403–9318) | <0.001  |
| Men                                     | 1354 (569–2543) | 903 (499–1860)   | 6234 (5315–7147) | <0.001  |
| Women                                   | 1388 (706–3297) | 1161 (560–2339) | 6402 (5485–9564) | <0.001  |
| AR grade≥moderate after TAVI            | 1931 (1104–2107) | 1660 (1049–2012) | 5659 (5659–5659)* | 0.222  |
| AR grade <moderate after TAVI           | 1371 (645–3145) | 1152 (540–2213) | 6407 (5419–9659) | <0.001  |
| Time from TAVI (days)                   | 9 (7–15)    | 9 (7–15)             | 12 (8–16)           | 0.003   |
| Age (years)                             | 86 (82–89)  | 86 (82–89)           | 86 (84–89)          | 0.191   |
| Men                                     | 121 (24.2)  | 104 (24.7)           | 17 (21.5)           | 0.544   |
| BSA (m2)                                | 1.39 (1.29–1.51) | 1.40 (1.30–1.52) | 1.33 (1.26–1.44) | 0.004   |
| **Atherosclerotic risks**               |             |                      |                     |         |
| Hypertension                            | 391 (78.2)  | 326 (77.4)           | 65 (82.3)           | 0.339   |
| Dyslipidaemia                           | 200 (40.0)  | 177 (42.0)           | 23 (29.1)           | 0.031   |
| Diabetes mellitus                       | 126 (25.2)  | 104 (24.7)           | 22 (27.8)           | 0.555   |
| Current smoking                         | 8 (1.6)     | 7 (1.7)              | 1 (1.3)             | 0.796   |
| Atrial fibrillation                     | 96 (19.2)   | 74 (17.6)            | 22 (27.8)           | 0.033   |
| Prior coronary artery bypass graft      | 37 (7.4)    | 33 (7.8)             | 4 (5.1)             | 0.387   |
| Previous myocardial infarction          | 44 (8.8)    | 31 (7.4)             | 13 (16.5)           | 0.009   |
| Previous ischaemic stroke              | 53 (10.6)   | 48 (11.4)            | 5 (6.3)             | 0.179   |
| **NYHA class**                          |             |                      |                     | 0.001   |
| Class II                                | 258 (51.6)  | 229 (54.4)           | 29 (36.7)           | –       |
| Class III                               | 198 (39.6)  | 160 (38.0)           | 38 (48.1)           | –       |
| Class IV                                | 27 (5.4)    | 17 (4.0)             | 10 (12.7)           | –       |
| Clinical Frailty Scale                  | 4 (3–5)     | 4 (3–4)              | 4 (3–6)             | 0.001   |
| **Medical treatment on admission**      |             |                      |                     |         |
| ACE-I or ARB                            | 303 (60.6)  | 259 (61.5)           | 44 (55.7)           | 0.331   |
| Beta-blocker                            | 207 (41.4)  | 166 (39.4)           | 41 (51.9)           | 0.039   |
| Ca blocker                              | 224 (44.8)  | 193 (45.8)           | 31 (39.2)           | 0.279   |
| Diuretics                               | 298 (59.6)  | 239 (56.8)           | 59 (74.7)           | 0.003   |
| Statin                                  | 233 (46.6)  | 209 (49.6)           | 24 (30.4)           | 0.002   |
| **Laboratory data on admission**        |             |                      |                     |         |
| NT-proBNP (pg/mL)                       | 1854 (718–4343) | 1473 (598–3298) | 5909 (3095–13202) | <0.001  |
| e-GFR (mL/min/1.73 m²)                  | 49.7 (37.6–61.3) | 51.1 (40.2–64.0) | 37.8 (28.6–51.6) | <0.001  |
| **TTE data before TAVI**                |             |                      |                     |         |
| LV end-diastolic diameter (mm)          | 43 (39–48)  | 43 (39–47)           | 44 (39–49)          | 0.312   |
| LV end-systolic diameter (mm)           | 28 (25–33)  | 28 (25–32)           | 29 (26–34)          | 0.067   |
| LVEF (%)                                | 63 (55–67)  | 63 (55–67)           | 58 (46–65)          | 0.001   |
| Mean AVP gradient (mm Hg)               | 47.9 (37.0–61.7) | 48.4 (37.0–62.7) | 47.3 (35.8–56.9) | 0.243   |
| Peak AVP gradient (mm Hg)               | 83.4 (65.0–106.0) | 84.0 (65.0–108.0) | 80.3 (63.0–95.0) | 0.257   |
| AVA with Doppler (cm²)                  | 0.60 (0.50–0.70) | 0.60 (0.50–0.71) | 0.60 (0.49–0.70) | 0.776   |
| STS score                               | 7.1 (5.1–9.8) | 6.9 (4.9–9.2)   | 9.8 (6.3–15.3) | <0.001  |
| Logistic EuroSCORE                      | 13.5 (9.5–20.7) | 12.8 (9.2–20.1) | 18.4 (11.2–25.6) | 0.001   |
| Euro II score                           | 3.6 (2.3–5.5) | 3.5 (2.2–5.2)   | 4.9 (3.4–8.0) | <0.001  |

Categorical variables are shown as numbers (percentages) and continuous variables are shown as medians (25–75 percentiles).

*Only one patient was categorised in this group.

ACE-I, angiotensin converting- enzyme inhibitor; AR, aortic regurgitation; ARB, angiotensin II receptor blocker; AVA, aortic valve area; AVP, aortic valve pressure; BSA, body surface area; e-GFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LV, left ventricle; LVEF, left ventricular ejection fraction by modified Simpson or Teichholz methods; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; STS, Society of Thoracic Surgeon; TAVI, transcatheter aortic valve implantation; TTE, transthoracic echocardiography.
was 1.47 cm². Periprocedural complications defined by Valve Academic Research Consortium-2 consensus, including coronary obstruction, permanent pacemaker implantation, and acute kidney injury, occurred in 1.0%, 6.6%, and 8.8% of the study participants, respectively. Furthermore, the incidences of life-threatening or disabling bleeding and minor bleeding in the high NT-proBNP group were significantly higher than those in the low NT-proBNP group.

During the 2-year follow-up period, there were 37 mortality events and 32 hospitalisation events due to HF. Figure 3 shows the Kaplan-Meier estimates of each endpoint following discharge. The primary endpoint occurred in 13.0% (95% CI 9.5% to 16.3%) at 1 year and 22.3% (95% CI 16.1%–27.9%) at 2 years. All-cause mortality was 6.7% (4.0%–9.3%) at 1 year and 16.0% (10.2%–21.4%) at 2 years; hospitalisation rates for HF were 7.2% (4.6%–9.8%) at 1 year and 9.2% (5.7%–12.6%) at 2 years. The survival CART analysis revealed that the NT-proBNP level at discharge required to discern the 2-year composite endpoint was 4288 pg/mL; hence, we divided the study population into two NT-proBNP groups, based on this result. Patients in the low NT-proBNP group were defined as having NT-proBNP at discharge ≤4288 pg/mL, and patients in the high NT-proBNP group were defined as having NT-proBNP at discharge >4288 pg/mL.

Comparisons between the low and high NT-proBNP groups showed a number of significant differences in patient characteristics and procedure-related indices (Tables 1, 2). The high NT-proBNP group had a higher proportion of factors associated with increased procedural risks, such as increased third quartile CFS, decreased estimated glomerular filtration rate, reduced LVEF and higher STS and logistic EuroSCORE, than the low NT-proBNP group. Moreover, the Kaplan-Meier estimates clarified that the 2-year composite endpoint of all-cause mortality and hospitalisation for HF was higher in the high NT-proBNP group than in the low NT-proBNP group, with log-rank P<0.001 (Figure 3).

Specifically, the composite endpoint of all-cause mortality and hospitalisation for HF was 30.3% (95% CI 17.8% to 40.6%) versus 9.5% (95% CI 6.2% to 12.8%) at 1 year and 41.9% (95% CI 23.9% to 55.7%) versus 18.5% (95% CI 17.8% 12.0%–24.6%) at 2 years in the high NT-proBNP and low NT-proBNP groups, respectively. Table 3 demonstrates that high NT-proBNP levels had a statistically significant impact on outcomes, with an adjusted HR of 2.21 (95% CI 1.21 to 4.04, p=0.010) for the primary endpoint and adjusted HR of 2.66 (1.13–6.25, p=0.026) for hospitalisation due to HF in a standard multivariable model, with a statistically significant difference between men and women for the primary endpoint (P for interaction<0.001) and hospitalisation for HF (P for interaction<0.001).

**DISCUSSION**

We demonstrated that elevated NT-proBNP levels at discharge were associated with higher 2-year composite events of all-cause mortality and hospitalisation for HF, and provided risk stratification cut-off values of NT-proBNP after TAVI via enrollment of the largest relevant study population ever (n=500), from the multicentre, prospective OCEAN-TAVI registry. As a result, we revealed that the best risk stratification NT-proBNP level at discharge was 4288 pg/mL. Regarding secondary endpoints, elevation of NT-proBNP was associated with increased risk of HF hospitalisation, but not with all-cause mortality. As none of the previous studies evaluated whether NT-proBNP levels at discharge were relevant to long-term prognosis following TAVI, even in this HF pandemic era, our study could provide physicians with new insights into this field.

**NT-proBNP at discharge**

Previous studies have provided evidence that NT-proBNP is greatly valuable as a risk stratification marker in patients with HF due to a wide spectrum of cardiovascular diseases. However, previous studies described the relationship between NT-proBNP levels before the TAVI procedure and patient prognosis, and many of these data were derived from single-centre studies that only focused on all-cause mortality, without describing the incidence of HF. For example, Ribeiro et al reported that a high baseline NT-proBNP was associated with a higher all-cause and cardiovascular mortality, as well as higher incidence of rehospitalisation for HF, in a single-centre study that included 333 patients, where differences in event rates might arise in the very early period after TAVI. In contrast, Köhler et al suggested that preprocedural NT-proBNP was in fact not associated with all-cause mortality at a median of 290 days, in a multivariable analysis based on data from 259 patients in a single-centre prospective study. Considering the short half-life of NT-proBNP (approximately 120 min) and the association between high baseline NT-proBNP and high short-term mortality risk, we believe that NT-proBNP level at discharge would be more beneficial than preprocedural NT-proBNP level for risk stratification of long-term prognosis after TAVI because the
TAVI procedure immediately improves left ventricular pressure overload.\textsuperscript{13-16} However, we also must keep in mind that direct comparison of preprocedural and postprocedural NT-proBNP values is needed to reach a conclusion of this issue, as it is controversial with B-type natriuretic peptide (BNP).\textsuperscript{17-23}

**Long-term prognosis after TAVI**

In this study, we found that elevated NT-proBNP levels at discharge were independently associated with a higher 2-year composite endpoint consisting of all-cause mortality and hospitalisation for HF. It seemed that differences in the incidence of the primary endpoint were mainly due to differences in the incidence of HF hospitalisation rather than all-cause mortality (figure 3). In fact, the adjusted HR of hospitalisation for HF was higher than that of all-cause mortality (2.66 vs 1.23). Although the management of HF become ever more important with improvements in

### Table 2  Procedural and periprocedural data

| Parameters | Total n=500 | Low NT-proBNP n=421 | High NT-proBNP n=79 | P values |
|------------|------------|---------------------|---------------------|----------|
| **Procedural data** | | | | |
| Apical approach | 108 (21.6) | 81 (19.2) | 27 (34.2) | 0.003 |
| Valve type | | | | 0.284 |
| Edwards SAPIEN XT | 425 (85.0) | 355 (84.3) | 70 (88.6) | |
| Edwards SAPIEN 3 | 33 (6.6) | 31 (7.4) | 2 (2.5) | |
| Medtronic CoreValve | 42 (8.4) | 35 (8.3) | 7 (8.9) | |
| Valve size (mm) | 23 (23–26) | 23 (23–26) | 23 (23–26) | 0.767 |
| Fluoro time (min) | 20 (16–27) | 21 (16–27) | 19 (15–27) | 0.518 |
| Procedure time (min) | 86 (66–108) | 83 (65–104) | 93 (77–118) | 0.007 |
| Anaesthesia time (min) | 152 (125–180) | 150 (124–179) | 159 (132–185) | 0.115 |
| **TTE Data after TAVI** | | | | |
| LV end-diastolic diameter (mm) | 44 (40–48) | 43 (40–47) | 45 (40–50) | 0.109 |
| LV end-systolic diameter (mm) | 28 (25–32) | 28 (25–31) | 30 (26–36) | 0.005 |
| LVEF (%) | 62 (55–67) | 63 (57–67) | 57 (50–63) | <0.001 |
| Mean AVP gradient (mm Hg) | 10.5 (8.0–13.2) | 11.0 (8.0–13.7) | 9.3 (7.1–12.5) | 0.048 |
| Peak AVP gradient (mm Hg) | 20.0 (15.4–26.0) | 20.2 (15.5–26.2) | 18.2 (15.0–23.2) | 0.057 |
| Effective orifice area (cm\(^2\)) | 1.47 (1.25–1.71) | 1.49 (1.28–1.73) | 1.40 (1.21–1.62) | 0.072 |
| AR grade ≥ moderate | 9 (1.8) | 8 (1.9) | 1 (1.3) | 0.703 |
| MR grade ≥ moderate | 42 (8.5) | 34 (8.1) | 8 (10.3) | 0.532 |
| **Periprocedural complications by VARC-2 definitions** | | | | |
| Coronary obstruction | 5 (1.0) | 5 (1.2) | 0 (0.0) | 0.330 |
| Periprocedural MI | 3 (0.6) | 3 (0.7) | 0 (0.0) | 0.452 |
| Stroke | 10 (2.0) | 10 (2.4) | 0 (0.0) | 0.166 |
| TIA | 2 (0.4) | 1 (0.2) | 1 (1.3) | 0.184 |
| Life-threatening or disabling bleeding | 31 (6.2) | 21 (5.0) | 10 (12.7) | 0.009 |
| Major bleeding | 53 (10.6) | 44 (10.5) | 9 (11.4) | 0.803 |
| Minor bleeding | 102 (20.4) | 76 (18.1) | 26 (32.9) | 0.003 |
| Major vascular complications | 19 (3.8) | 13 (3.1) | 6 (7.6) | 0.055 |
| Minor vascular complications | 29 (5.8) | 26 (6.2) | 3 (3.8) | 0.407 |
| Conduction disturbances and arrhythmias | 59 (11.9) | 50 (12.0) | 9 (11.4) | 0.880 |
| Permanent PM implantation | 33 (6.6) | 25 (5.9) | 8 (10.1) | 0.169 |
| Acute kidney injury | 44 (8.8) | 25 (5.9) | 19 (24.1) | <0.001 |

AR, aortic regurgitation; AVP, aortic valve pressure; LV, left ventricle; LVEF, left ventricular ejection fraction by modified Simpson or Teichholz methods; MI, myocardial infarction; MR, mitral regurgitation; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PM, pacemaker; TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack; TTE, transthoracic echocardiography; VARC-2, Valve Academic Research Consortium-2.
midterm survival and prolongation of life expectancy following TAVI, most previous studies on NT-proBNP in patients who underwent TAVI procedures did not focus on hospitalisation for HF.\textsuperscript{10–15} Thus, to the best of our knowledge, this is the first report to examine the association between NT-proBNP at discharge and hospitalisation for HF following TAVI, using a multicentre prospective large cohort data set. In contrast, we previously reported the significant association between the BNP at discharge and 2-year mortality from the same registry.\textsuperscript{17} This discrepancy, regarding the associations with all-cause mortality between NT-proBNP and BNP, may be mainly derived from a relatively small number of patients (n=500 vs 1094), considering an estimated statistical power for the log-rank test of 0.167 with the current number of patients and event rates.

**Sex differences**

In the present study, the proportion of male participants was relatively low (24.2\%) in comparison with those in studies in Western countries.\textsuperscript{3–5,25} Although several previous studies reported higher NT-proBNP levels in women than in men in the general population,\textsuperscript{26} NT-proBNP levels at discharge were not statistically significantly different between the men and the women in our cohort. This sex disparity should be taken into consideration when interpreting our data. The impact of elevated NT-proBNP levels at discharge on the primary endpoint and hospitalisation for HF was statistically greater in the female than in the male patients, with p values for interaction of 0.003 and <0.001, respectively. This is consistent with a previous report that demonstrated different predictors of survival between men and women after TAVI.\textsuperscript{27}

**Clinical implications**

As TAVI cohorts are generally aged and often have complications due to multiple risk factors that can affect their prognoses, we believe that a simple risk stratification model is helpful for physicians to support better patient care, especially those with HF. NT-proBNP has already been used for this purpose in a wide spectrum of cardiovascular diseases.\textsuperscript{1,2,7–9} From this viewpoint, we employed survival CART and revealed that patients in the high NT-proBNP group, defined as those with...
NT-proBNP at discharge $>4288 \text{ pg/mL}$, should be carefully followed up in outpatient care to ensure hospitalisation for HF and/or decrease the composite of all-cause mortality and HF hospitalisation.

**Limitations**

This study had several limitations. First, the NT-proBNP values collected were not measured in a core laboratory but at individual OCEAN-TAVI registry institutions using different methods rather than at a single core laboratory; however, the assay methods were highly comparable. To minimise this problem, we performed multivariable Cox regression analysis, with each institution as a stratum. Second, the decision to hospitalise patients was individually judged by each attending physician, without adherence to any pre-specified criteria. However, we had a consensus indication for HF hospitalisation. Third, our clinical data from the OCEAN-TAVI registry had a relatively low proportion of males as compared with previous studies in Western countries.$^{3,4,5,17,25}$ Lastly, we did not evaluate the impact of NT-proBNP level on admission and compare it with that at discharge. This should be evaluated in future research.

**CONCLUSION**

Elevation of NT-proBNP at discharge is associated with 2-year all-cause mortality and hospitalisation for HF after TAVI.

### Table 3 Impact of NT-proBNP stratification on outcomes

| Endpoint                  | Univariable | Multivariable | AIC based multivariable |
|---------------------------|-------------|---------------|-------------------------|
|                           | HR (95% CI) | P values      | Adjusted HR (95% CI)    | P values       | Adjusted HR (95% CI)       | P values |
| Composite                 |             |               |                         |                |                          |          |
| Men                       | 3.44 (2.06 to 5.76) | <0.001 | 2.21 (1.21 to 4.04) | 0.010 | 2.76 (1.60 to 4.77) | <0.001 |
| Women                     | 5.03 (2.73 to 9.27) | <0.001 | 3.69 (1.86 to 7.34) | <0.001 | 4.29 (2.29 to 8.04) | <0.001 |
| All-cause mortality       |             |               |                         |                |                          |          |
| Men                       | 1.77 (0.83 to 3.75) | 0.137 | 1.23 (0.51 to 2.97) | 0.642 | –             | –          |
| Women                     | 2.03 (0.85 to 4.83) | 0.112 | 2.11 (0.78 to 5.71) | 0.142 | –             | –          |
| Hospitalisation for HF    |             |               |                         |                |                          |          |
| Men                       | 4.44 (2.21 to 8.94) | <0.001 | 2.66 (1.13 to 6.25) | 0.026 | 2.78 (1.26 to 6.13) | 0.011 |
| Women                     | 0.98 (0.22 to 4.40) | 0.983 | 0.08 (0.00 to 3.76) | 0.197 | 0.12 (0.01 to 1.32) | 0.084 |
| Women                     | 11.13 (4.18 to 29.67) | <0.001 | 7.10 (2.31 to 21.83) | <0.001 | 9.66 (3.36 to 27.79) | <0.001 |

In a multivariable model, the adjusted HR of high N-terminal pro-B-type natriuretic peptide (NT-proBNP) as compared with that of low NT-proBNP was calculated by adjusting the following variables with a cross-product term between NT-proBNP groups and sex for the assessment of sex differences, with a $P$ for interaction: Clinical Frailty Scale, Society of Thoracic Surgeons score, apical approach, left ventricle (LV) ejection fraction, effective orifice area, mean aortic valve pressure gradient (AVPG), moderate to severe aortic regurgitation, acute kidney injury after TAVI and institution as a stratum. The AIC model selected mean AVPG as a covariate for composite endpoint, and mean AVPG and LV ejection fraction as covariates for heart failure hospitalisation. AIC, Akaike Information Criteria.

### Author affiliations

1Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
2Center for Community-based Healthcare Research and Education, Shimane University, Izumo, Japan
3Department of Cardiovascular Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
4Department of Cardiology, New Tokyo Hospital, Matsudo, Japan
5Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
6Department of Cardiology, Kishiwada Tokusyukai Hospital, Kishiwada, Japan
7Department of Cardiology, Sendai Kousei Hospital, Sendai, Japan
8Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan
9Department of Cardiology, Saiaseiki Yokohama City Eastern Hospital, Yokohama, Japan
10Second Department of Internal Medicine, University of Toyama, Toyama, Japan
11Department of Cardiovascular Surgery, Tokyo Bay Urayasu-Ichikawa Medical Center, Urayasu, Japan
12Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan
13Department of Cardiology, Teikyo University School of Medicine, Toyoohashi, Japan
14Department of Cardiology, Toyoohashi Heart Center, Toyoohashi, Japan
15Department of Cardiology, Keio University School of Medicine, Tokyo, Japan

### Acknowledgements

We would like to express our heartfelt gratitude to the Japan Society of Clinical Research for their dedicated support.

### Contributors

KM, MH, MN, TO, KK, TM, FN, FY, AH, NT, KT, MA, HU, MT, SS, YW, MY and KH: substantial contributions to the conception or design of the work and acquisition of data. KM, MH: analysis of data and preparation of initial draft for the manuscript. TS and MY: Supervision of initial draft for the manuscript. All authors: interpretation of data, drafting the work or revising it critically for important intellectual content and final approval of the version published.

### Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

### Competing interests

KH, SS, MT, MA, KT and NT are clinical proctors for Edwards Lifesciences. MY, YW and TN are clinical proctors for both Edwards Lifesciences and Medtronic.
REFERENCES

1. Maganti K, Rigolin VH, Sarano ME, et al. Valvular heart disease: diagnosis and management. *Mayo Clin Proc* 2010;85:483–500.

2. Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;63:e13–24.

3. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011;364:2187–98.

4. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;363:1597–607.

5. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Patients. *N Engl J Med* 2016;374:1609–20.

6. Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. *BMJ* 2016;354:i310.

7. Daniels LB, Maisel AS, peptides *N Engl J Cardiol* 2007;50:2357–68.

8. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. *Circulation* 2004;110:1780–6.

9. Bergler-Klein J, Klaar U, Hegar M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. *Circulation* 2004;109:2302–8.

10. Köhler WM, Freitag-Wolf S, Lambers M, et al. Preprocedural but not periprocedural high-sensitive Troponin T levels predict outcome in patients undergoing transcatheter aortic valve implantation. *Catheter Cardiovasc Ther* 2016;84:385–96.

11. Stähli BE, Gebhard C, Saleh L, et al. N-terminal pro-B-type natriuretic peptide ratio predicts mortality after transcatheter aortic valve replacement. *Catheter Cardiovasc Interv* 2015;85:1240–7.

12. Ribeiro HB, Urena M, Le Ven F, et al. Long-term prognostic value and serial changes of plasma N-terminal prohormone B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation. *Am J Cardiol* 2014;113:851–9.

13. Elhmdy Y, Bleiziffer S, Piazza N, et al. The evolution and prognostic value of N-terminal brain natriuretic peptide in predicting 1-year mortality in patients following transcatheter aortic valve implantation. *J Invasive Cardiol* 2013;25:38–44.

14. Spargias K, Polymeros S, Dimopoulos A, et al. The predictive value and evolution of N-terminal pro-B-type natriuretic peptide levels following transcatheter aortic valve implantation. *J Interv Cardiol* 2011;24:462–9.

15. Pfister R, Wahlers T, Baer FM, et al. Utility of NT-pro-BNP in patients undergoing transapical aortic valve replacement. *Clin Res Cardiol* 2010;99:301–7.

16. Mair J. Biochemistry of B-type natriuretic peptide—where are we now? *Clin Chem Lab Med* 2008;46:1507–14.

17. Mizutani K, Hara M, Ikawa S, et al. Elevation of B-Type Natriuretic Peptide at Discharge is Associated With 2-Year Mortality After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Insights From a Multicenter Prospective OCEAN-TAVI (Optimized Transcatheter Valvular Intervention-Transcatheter Aortic Valve Implantation) Registry. *J Am Heart Assoc* 2017;6:e006112.

18. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *J Am Coll Cardiol* 2012;60:1438–54.

19. Hara M, Sakata Y, Nakatani D, et al. Subclinical elevation of high-sensitive troponin T levels at the convalescent stage is associated with increased 5-year mortality after ST-elevation myocardial infarction. *J Cardiol* 2016;67:314–20.

20. Fonarow GC, Adams KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. *JAMA* 2005;293:572–80.

21. Abramowicz Y, Chakravarty T, Jilaihawi H, et al. Impact of Preprocedural B-Type Natriuretic Peptide Levels on the Outcomes After Transcatheter Aortic Valve Implantation. *Am J Cardiol* 2015;116:1904–9.

22. Giordana F, D’Ascenzo F, Nijhoff F, et al. Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation. *Am J Cardiol* 2014;114:1447–54.

23. Koskinas KC, O’Sullivan CJ, Heg D, et al. Effect of B-type natriuretic peptides on long-term outcomes after transcatheter aortic valve implantation. *Am J Cardiol* 2015;116:1560–5.

24. Parikh V, Kim C, Siegel RJ, et al. Natriuretic peptides for risk stratification of patients with valvular aortic stenosis. *Circ Heart Fail* 2015;8:373–80.

25. Shimura T, Yamamoto M, Kano S, et al. Impact of the Clinical Frailty Scale on Outcomes After Transcatheter Aortic Valve Replacement. *Circulation* 2017;135:2013–24.

26. Lubnauer A, Behrens G, Stritzke J, et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. *Eur J Heart Fail* 2013;15:859–67.

27. Conrotto F, D’Ascenzo F, Salizzoni S, et al. A gender based analysis of predictors of all cause death after transcatheter aortic valve implantation. *Am J Cardiol* 2014;114:1269–74.